NCT01327469

Brief Summary

The major soil-transmitted helminths (STHs), Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm) and Necator americanus/Ancylostoma duodenal (hookworms) are amongst the most prevalent parasites worldwide. An estimated 4.5 billion individuals are at risk for STH and more than one billion individuals are thought to be infected, of which 450 million have significant morbidity attributable from their infection, school-aged children in particular. In this population infections cause stunting of the linear growth, anemia, reduce the cognitive function and contribute to the existing malnutrition. In Jimma (Ethiopia), STH are highly prevalent, affecting more than 60% of the children (data not published). Current efforts to control STH infections involve periodic mass drug anthelmintic treatment of infected children in endemic areas and are likely to intensify as more attention is addressed to the importance of these neglected diseases. Monitoring drug efficacy in these control programs has become indispensable in order to detect the emergence of resistance and/or identify confounding factors affecting the drug efficacy. Recently a study has evaluated a single dose albendazole (ALB) in school age children across 7 countries, including Ethiopia, revealing that this regime is highly efficacious for the treatment of A. lumbricoides (99.5%) and hookworms (94.8%), but not for T. trichiura (50.8%). For this parasite a repeated dose regime of ALB on consecutive days is likely to be more appropriate. Alternative drugs are mebendazole (single dose 500mg) and pyrantel+oxantel (single dose 10mg/kg), of which the latter holds promise as it can also be administrated to children between 6 months and 2 years. The main objective of the present study, therefore, is to assess the efficacy of 5 different treatment regimes against T. trichiura in schoolchildren in Jimma, Ethiopia, including albendazole (1 x 400mg, 2 x 400mg), mebendazole (1 x 500mg, 2x 500mg) and pyrantel-oxantel (10mg/kg)+mebendazole (500mg).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,250

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Dec 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2011

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

March 30, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 1, 2011

Completed
Last Updated

April 1, 2011

Status Verified

March 1, 2011

Enrollment Period

2 months

First QC Date

March 30, 2011

Last Update Submit

March 31, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy against T. trichiura of various treatment regimes

    The evaluation of the efficacy against T. trichiura of various treatment regimes. To this end, subjects infected with T. trichura (based on McMaster), will be randomly assigned to one of the five proposed treatment regimes. Two weeks after the treatment, faecal egg counts will be performed and the reduction in faecal egg counts will be evaluated

    After two weeks treatment

Study Arms (5)

Albendazole 400mg

EXPERIMENTAL

albendazole, 1 x 400mg

Drug: Albendazole 400mg

Albendazole 2 x 400mg

EXPERIMENTAL

albendazole, 2 x 400mg

Drug: Albendazole, 2 x 400mg

Mebendazole 500mg

EXPERIMENTAL

mebendazole, 1 x 500mg

Drug: Mebendazole 500mg

Mebendazole 2 x 500mg

EXPERIMENTAL

mebendazole, 2x 500mg

Drug: Mebendazole 2 x 500mg

Pyrantel-oxantel + mebendazole

EXPERIMENTAL

pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)

Drug: Pyrantel-oxantel + mebendazole

Interventions

Albendazole 400mg

Albendazole 400mg

Albendazole 2 x 400mg

Albendazole 2 x 400mg

Mebendazole 500mg

Mebendazole 500mg

Mebendazole 2 x 500mg

Mebendazole 2 x 500mg

Pyrantel-oxantel + mebendazole

Pyrantel-oxantel + mebendazole

Eligibility Criteria

Age4 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • all school age children who are eligible to participate in the study

You may not qualify if:

  • Not willing to participate (no informed consent)
  • Unable to give samples for follow up
  • Severe intercurrent medical condition
  • Diarrhea at first sampling
  • Study subjects who had treatment for STH in the last 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jimma University

Jimma, Ethiopia

Location

Related Publications (1)

  • Levecke B, Mekonnen Z, Albonico M, Vercruysse J. The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura. Trans R Soc Trop Med Hyg. 2012 Feb;106(2):128-30. doi: 10.1016/j.trstmh.2011.09.007. Epub 2011 Dec 19.

MeSH Terms

Conditions

Trichuriasis

Interventions

AlbendazoleMebendazole

Condition Hierarchy (Ancestors)

Enoplida InfectionsAdenophorea InfectionsNematode InfectionsHelminthiasisParasitic DiseasesInfections

Intervention Hierarchy (Ancestors)

CarbamatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Jozef Vercruysse, PhD

    University Ghent

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 30, 2011

First Posted

April 1, 2011

Study Start

December 1, 2010

Primary Completion

February 1, 2011

Study Completion

March 1, 2011

Last Updated

April 1, 2011

Record last verified: 2011-03

Locations